L
Laekna Inc
HKEX:2105
Laekna Inc
HKEX:2105
Price:
13.95
HKD
-0.36%
Market Closed
Market Cap:
HK$6.2B
Relative Value
The Relative Value of one Laekna Inc stock under the Base Case scenario is 1.73 HKD. Compared to the current market price of 13.95 HKD, Laekna Inc is Overvalued by 88%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
Relative Value
Base Case
1.73
HKD
Overvaluation 88%
L
Multiples Across Competitors
Competitors Multiples
Laekna Inc Competitors
Laekna Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CN |
L
|
Laekna Inc
HKEX:2105
|
5.7B HKD | 0 | -20.8 | -15.6 | -15.6 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
398.4B USD | 6.5 | 95.2 | 15.6 | 21.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
198.2B USD | 5.4 | 25.7 | 14.8 | 14.8 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
180.2B USD | 6.1 | 21.2 | 13.2 | 16.3 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121.4B USD | 10.1 | 30.7 | 23.2 | 24.2 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78.9B USD | 5.5 | 17.5 | 13 | 14.8 | |
| AU |
|
CSL Ltd
ASX:CSL
|
68B AUD | 3.1 | 34.5 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 | |
| NL |
|
argenx SE
XBRU:ARGX
|
37.7B EUR | 10.8 | 34.6 | 37.5 | 38.3 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
